NOVARTIS PHARMACEUTICALS CORPORATION v. BECERRA et al
Case Number:
1:25-cv-00117
Court:
Nature of Suit:
Administrative Procedure Act/Review or Appeal of Agency Decision
Judge:
Firms
Companies
- American Hospital Association
- America's Essential Hospitals
- Arkansas Hospital Association
- Association of American Medical Colleges
- Biotechnology Innovation Organization
- California Hospital Association
- Florida Hospital Association Inc.
- Genesis HealthCare Corp.
- Georgia Hospital Association
- Greater New York Hospital Association
- Healthcare Association of Hawaii
- Indiana Hospital Association
- Iowa Hospital Association
- Kentucky Hospital Association
- Louisiana Hospital Association
- Michigan Health & Hospital Association
- Mississippi Hospital Association
- Missouri Hospital Association
- New Jersey Hospital Association
- Pharmaceutical Research & Manufacturers of America
- Texas Hospital Association
- The Hospital and Healthsystem Association of Pennsylvania
- UMass Memorial Health Care Inc.
- West Virginia Hospital Association
- Wisconsin Hospital Association
Sectors & Industries:
-
March 18, 2025
Texas Abortion Charges, HHS Rehirings And FTC Deal Warning
The Trump administration is seeking an emergency halt of a Maryland federal court order that led the Department of Health and Human Services to delay the terminations of almost 3,000 probationary employees, arguing it has burdened HHS and over a dozen other federal agencies behind the mass firings. Here, Law360 Healthcare Authority looks at these and other significant cases and decisions that shaped the healthcare industry over the last week.
-
March 18, 2025
HHS Seeks Early Win Over Lilly, Novartis, BMS In Rebate Row
The U.S. Department of Health and Human Services urged a D.C. federal judge Monday to grant it an early win against behemoth drugmakers' claims that it unlawfully blocked their plans to offer after-the-fact rebates, rather than up-front discounts, to safety-net hospitals via a decades-old federal drug pricing program.
-
February 18, 2025
340B Rebate Clash Triggers 5 Suits By Drugmakers
The federal agency overseeing the 340B drug pricing program faces five distinct legal challenges by drugmakers that say the agency illegally blocked their plans to offer rebates rather than upfront discounts to participating hospitals.